Table 10.6a

Immunosuppression Use for Induction, 1997 to 2006

Recipients with Intestine Transplants

  Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 68 70 73 82 112 107 116 152 176 174
With Immunosuppression Info 66 68 71 80 112 106 116 149 165 168
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 3.0% 0.0% 0.0% 1.3% 0.0% 0.9% 1.7% 2.7% 1.8% 0.6%
OKT3 4.5% 2.9% 9.9% 5.0% 6.3% 1.9% 1.7% 1.3% 3.6% 14.3%
Thymoglobulin 0.0% 0.0% 4.2% 0.0% 12.5% 31.1% 45.7% 18.8% 15.2% 17.9%
Zenapax 0.0% 36.8% 49.3% 55.0% 24.1% 12.3% 17.2% 12.8% 13.9% 17.3%
Simulect 0.0% 1.5% 1.4% 12.5% 13.4% 13.2% 1.7% 0.7% 3.0% 3.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 8.6% 19.5% 22.4% 21.4%
No Induction Drugs Recorded 92.4% 58.8% 39.4% 31.3% 43.8% 39.6% 25.0% 45.6% 45.5% 41.7%


Source: OPTN/SRTR Data as of May 1, 2007.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.